At a glance
ClinicalIndex Comparison RecordN/ACompleted· 300 enrolled
Drug / intervention
Tirbanibulindrug
Likely dose
Tirbanibulin 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Cohort Study of Patients With Actinic Keratosis (AK) in the Face or Scalp Treated With Tirbanibulin and Followed for 24 Weeks Post Treatment-initiation. Patient Reported Outcomes (PROs) and Clinical Profile of Patients Will be Gathered for Descriptive Analyses of Patient Outcomes Over the 24-week Study Observation Period
In Brief
An observational study evaluating Tirbanibulin for Keratosis, Actinic. Completed, enrolled 300 participants across 1 site.
Detailed Summary
The purpose of the study is to evaluate patient reported outcomes (PROs) in terms of health-related quality of life (HRQoL) among subjects with actinic keratosis (AK).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsKeratosis, Actinic
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartMar 2022
Primary CompletionOct 2022
Study CompletionMar 2023
TodayJul 2026
First PostedMar 2, 2022
Enrollment StartMar 9, 2022
Primary CompletionOct 31, 2022
Study CompletionMar 7, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.3 years ago
Interventions
Tirbanibulindrug
Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.